Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS
| Autor: | Rajat Kumar, Richard A. Wells, Michelle Geddes, Rena Buckstein, Thomas J. Nevill, Eve St. Hilaire, Brian Leber, John M. Storring, Mohamed Elemary, Nancy Zhu, Robert Delage, Mary-Margaret Keating, Karen Yee, April Shamy, Heather A. Leitch |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Canada Cancer Research medicine.medical_specialty Iron Overload Evidence-based practice 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Clinical endpoint Overall survival Humans Multicenter Studies as Topic Medicine In patient Intensive care medicine business.industry Myelodysplastic syndromes Organ dysfunction Myeloid leukemia Hematology medicine.disease Iron reduction Oncology Myelodysplastic Syndromes 030220 oncology & carcinogenesis Practice Guidelines as Topic Female medicine.symptom business 030215 immunology |
| Zdroj: | Leukemia Research. 74:21-41 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2018.09.005 |
| Popis: | In 2008 the first evidence-based Canadian consensus guideline addressing the diagnosis, monitoring and management of transfusional iron overload in patients with myelodysplastic syndromes (MDS) was published. The Canadian Consortium on MDS, comprised of hematologists from across Canada with a clinical and academic interest in MDS, reconvened to update these guidelines. A literature search was updated in 2017; topics reviewed include mechanisms of iron overload induced cellular damage, evidence for clinical endpoints impacted by iron overload including organ dysfunction, infections, marrow failure, overall survival, acute myeloid leukemia progression, and endpoints around hematopoietic stem-cell transplant. Evidence for an impact of iron reduction on the same endpoints is discussed, guidelines are updated, and areas identified where evidence is suboptimal. The guidelines address common questions around the diagnosis, workup and management of iron overload in clinical practice, and take the approach of who, when, why and how to treat iron overload in MDS. Practical recommendations for treatment and monitoring are made. Evidence levels and grading of recommendations are provided for all clinical endpoints examined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect